LexDanaLexDanabeta
Inventor

Hing L. Sham

Inventor
Gurnee, IL, US

Overview

91→
Patents
1988–2021
Patent span
Chemistry
Primary field (CPC C)

Patents· 91 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Dprimary
C07DHeterocyclic compounds33%
C07CAcyclic or carbocyclic compounds17%
A61KPreparations for medical, dental or toiletry purposes15%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations14%
C07KPeptides11%
C07BGeneral methods of organic chemistry4%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium2%
Y02PClimate change mitigation technologies in the production or processing of goods1%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests1%
PatentTitleYear
11,014,884Modulators of hemoglobin202110,144,746Bridged bicyclic kallikrein inhibitors20189,815,853'Bridged bicyclic kallikrein inhibitors'20179,796,706'Inhibitors of Jun N-terminal kinase'20179,695,166'Pyrazolopyridine pyrazolopyrimidine and related compounds'20179,493,485'Spirocyclic dihydro-thiazine and dihydro-oxazine BACE inhibitors, and compositions and uses thereof'20169,073,891'Inhibitors of Jun N-terminal kinase'20158,748,627'Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome'20148,735,595'Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome'20148,637,546'Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DDP-IV)'20148,450,363'Inhibitors of Jun N-terminal kinase'20138,207,350'Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome'20128,119,664'Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)'20127,968,707'Retroviral protease inhibiting compounds'20117,928,243'Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome'20117,888,374'Inhibitors of c-jun N-terminal kinases'20117,671,076'Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)'20107,456,169'Heterocyclic kinase inhibitors'20087,348,346'Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)'20087,323,570'Farnesyltransferase inhibitors'20087,320,986'Fused tri and tetra-cyclic pyrazole kinase inhibitors'20087,279,582'Retroviral protease inhibiting compounds'20077,262,207'Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)'20077,238,724'Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)'20077,211,595'Farnesyltransferase inhibitors'20077,205,409'Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)'20077,119,205'Thienopyridones as AMPK activators for the treatment of diabetes and obesity'20067,115,767'Tetraline derivatives as ghrelin receptor modulators'20067,071,182'Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor'20067,056,925'Urea kinase inhibitors'20067,049,307'Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor'20066,924,304'Cell proliferation inhibitors'20056,831,096'Inhibitors of neuraminidases'20046,797,825'Protein kinase inhibitors'20046,667,404'Retroviral protease inhibiting compounds'20036,521,658'Cell proliferation inhibitors'20036,518,305'Five-membered carbocyclic and heterocyclic inhibitors of neuraminidases'20036,472,529'Retroviral protease inhibiting compounds'20026,455,571'Inhibitors of neuraminidases'20026,313,296'Retroviral protease inhibiting compounds'20016,284,767'Retroviral protease inhibiting compounds'20016,228,868'Oxazoline antiproliferative agents'20016,201,001'Imidazole antiproliferative agents'20016,150,530'Retroviral protease inhibiting compounds'20006,017,928'Retroviral protease inhibiting compounds'20005,990,135'Retroviral protease inhibiting compounds'19995,914,332'Retroviral protease inhibiting compounds'19995,905,068'Retroviral protease inhibiting compounds'19995,892,052'Process for making retroviral protease inhibiting compounds'19995,886,036'Retroviral protease inhibiting compounds'19995,846,987'Retroviral protease inhibiting compounds'19985,696,270'Intermediate for making retroviral protease inhibiting compounds'19975,679,797'Retroviral protease inhibiting compounds'19975,674,882'Retroviral protease inhibiting compounds'19975,654,466'Process for the preparation of a disubstituted 2,5-diamino-3-hydroxyhexane'19975,648,497'Retroviral protease inhibiting compounds'19975,635,523'Retroviral protease inhibiting compounds'19975,631,376'Retroviral protease inhibiting compounds'19975,625,072'Retroviral protease inhibiting compounds'19975,625,092'Process for the preparation of a substituted 2.5-diamino-3-hydroxyhexane'19975,621,109'Retroviral protease inhibiting compounds'19975,616,714'Retroviral protease inhibiting compounds'19975,616,720'Retroviral protease inhibiting compounds'19975,608,072'Retroviral protease inhibiting compounds'19975,597,928'Retroviral protease inhibiting compounds'19975,597,927'Retroviral protease inhibiting compounds'19975,591,860'Retroviral protease inhibiting compounds'19975,583,232'Retroviral protease inhibiting compounds'19965,583,233'Retroviral protease inhibiting compounds'19965,580,984'Retroviral protease inhibiting compounds'19965,565,604'Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane'19965,565,418'Retroviral protease inhibiting compounds'19965,545,750'Retroviral protease inhibiting compounds'19965,543,552'Process for the prepartation of a substituted 2,5-diamino-3-hydroxyhexane'19965,543,551'Process for the preparation of a substituted 2.5-diamino-3-hydroxyhexane'19965,543,549'Process for the preparation of a substituted 2,5-Diamino-3-Hydroxyhexane'19965,541,206'Retroviral protease inhibiting compounds'19965,541,328'Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane'19965,539,122'Retroviral protease inhibiting compounds'19965,508,409'Process for the preparation of a substituted 2.5-diamino-3-hydroxyhexane'19965,491,253'Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane'19965,461,067'Retroviral protease inhibiting compounds'19955,455,351'Retroviral protease inhibiting piperazine compounds'19955,354,866'Retroviral protease inhibiting compounds'19945,268,374'Non-peptide renin inhibitors'19935,256,677'Retroviral protease inhibiting compounds'19935,151,438'Retroviral protease inhibiting compounds'19924,988,703'Carbocyclic nucleoside analogs with antiviral activity'19914,826,958'Renin inhibiting compounds'19894,826,815'Renin inhibiting compounds'19894,725,584'Peptidyl-1-amino-2,4-diols'1988

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1988–2012Patents assigned to ABBOTT LAB (78)· patent assignee history
1989–2003Based in Gurnee, IL, US· patent location history
1995–2011Based in Mundelein, IL, US· patent location history
2001–2014Based in Vernon Hills, IL, US· patent location history
2008–2021Based in South San Francisco, CA, US· patent location history
2012–2015Patents assigned to SHAM HING L (6)· patent assignee history
2012–2014Patents assigned to GU YU GUI (3)· patent assignee history
2013–2018Based in Palo Alto, CA, US· patent location history
2014Patents assigned to ABBVIE INC (3)· patent assignee history
2017–2021Patents assigned to GLOBAL BLOOD THERAPEUTICS INC (4)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
ABBOTT LAB781988–2012
SHAM HING Lself62012–2015
GLOBAL BLOOD THERAPEUTICS INC42017–2021
ABBVIE INC32014
GU YU GUI32012–2014
Locations
LocationPatentsSpan
Gurnee, Illinois, US321989–2003
Mundelein, Illinois, US271995–2011
Vernon Hills, Illinois, US182001–2014
South San Francisco, California, US72008–2021
Palo Alto, California, US62013–2018